Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer.


Journal

Nature cancer
ISSN: 2662-1347
Titre abrégé: Nat Cancer
Pays: England
ID NLM: 101761119

Informations de publication

Date de publication:
02 2020
Historique:
received: 06 11 2019
accepted: 14 01 2020
entrez: 5 2 2022
pubmed: 1 2 2020
medline: 1 2 2020
Statut: ppublish

Résumé

Genomic alterations shape cell phenotypes and the structure of tumor ecosystems in poorly defined ways. To investigate these relationships, we used imaging mass cytometry to quantify the expression of 37 proteins with subcellular spatial resolution in 483 tumors from the METABRIC cohort. Single-cell analysis revealed cell phenotypes spanning epithelial, stromal and immune types. Distinct combinations of cell phenotypes and cell-cell interactions were associated with genomic subtypes of breast cancer. Epithelial luminal cell phenotypes separated into those predominantly impacted by mutations and those affected by copy number aberrations. Several features of tumor ecosystems, including cellular neighborhoods, were linked to prognosis, illustrating their clinical relevance. In summary, systematic analysis of single-cell phenotypic and spatial correlates of genomic alterations in cancer revealed how genomes shape both the composition and architecture of breast tumor ecosystems and will enable greater understanding of the phenotypic impact of genomic alterations.

Identifiants

pubmed: 35122013
doi: 10.1038/s43018-020-0026-6
pii: 10.1038/s43018-020-0026-6
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

163-175

Subventions

Organisme : NIDDK NIH HHS
ID : UC4 DK108132
Pays : United States
Organisme : Cancer Research UK
Pays : United Kingdom

Investigateurs

H Raza Ali (HR)
M Al Sa'd (M)
S Alon (S)
Samuel Aparicio (S)
G Battistoni (G)
S Balasubramanian (S)
R Becker (R)
Bernd Bodenmiller (B)
E S Boyden (ES)
D Bressan (D)
A Bruna (A)
B Marcel (B)
Carlos Caldas (C)
M Callari (M)
I G Cannell (IG)
H Casbolt (H)
N Chornay (N)
Y Cui (Y)
A Dariush (A)
K Dinh (K)
A Emenari (A)
Y Eyal-Lubling (Y)
J Fan (J)
E Fisher (E)
E A González-Solares (EA)
C González-Fernández (C)
D Goodwin (D)
W Greenwood (W)
F Grimaldi (F)
G J Hannon (GJ)
O Harris (O)
S Harris (S)
C Jauset (C)
J A Joyce (JA)
E D Karagiannis (ED)
T Kovačević (T)
L Kuett (L)
R Kunes (R)
A Küpcü Yoldaş (A)
D Lai (D)
E Laks (E)
H Lee (H)
M Lee (M)
G Lerda (G)
Y Li (Y)
A McPherson (A)
N Millar (N)
C M Mulvey (CM)
F Nugent (F)
C H O'Flanagan (CH)
M Paez-Ribes (M)
I Pearsall (I)
F Qosaj (F)
A J Roth (AJ)
Oscar M Rueda (OM)
T Ruiz (T)
K Sawicka (K)
L A Sepúlveda (LA)
S P Shah (SP)
A Shea (A)
A Sinha (A)
A Smith (A)
S Tavaré (S)
S Tietscher (S)
I Vázquez-García (I)
S L Vogl (SL)
N A Walton (NA)
A T Wassie (AT)
S S Watson (SS)
S A Wild (SA)
E Williams (E)
J Windhager (J)
C Xia (C)
P Zheng (P)
X Zhuang (X)

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2020. The Author(s), under exclusive licence to Springer Nature America, Inc.

Références

Perou, C. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
pubmed: 10963602 doi: 10.1038/35021093
Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346–352 (2012).
pubmed: 22522925 pmcid: 3440846 doi: 10.1038/nature10983
Ali, H. R. et al. Genome-driven integrated classification of breast cancer validated in over 7,500 samples. Genome Biol. 15, 431 (2014).
pubmed: 25164602 pmcid: 4166472 doi: 10.1186/s13059-014-0431-1
Ciriello, G. et al. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45, 1127–1133 (2013).
pubmed: 24071851 pmcid: 4320046 doi: 10.1038/ng.2762
Pereira, B. et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat. Commun. 7, 11479 (2016).
pubmed: 27161491 pmcid: 4866047 doi: 10.1038/ncomms11479
Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47–54 (2016).
pubmed: 27135926 pmcid: 4910866 doi: 10.1038/nature17676
Wagner, J. et al. A single-cell atlas of the tumor and immune ecosystem of human breast cancer. Cell 177, 1330–1345 (2019).
pubmed: 30982598 pmcid: 6526772 doi: 10.1016/j.cell.2019.03.005
Giesen, C. et al. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat. Methods 11, 417–422 (2014).
pubmed: 24584193 doi: 10.1038/nmeth.2869
Dvinge, H. et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 497, 378–382 (2013).
pubmed: 23644459 doi: 10.1038/nature12108
Schulz, D. et al. Simultaneous multiplexed imaging of mRNA and proteins with subcellular resolution in breast cancer tissue samples by mass cytometry. Cell Syst. 6, 25–36 (2018).
Damond, N. et al. A map of human type 1 diabetes progression by imaging mass cytometry. Cell Metab. 29, 755–768 (2019).
pubmed: 30713109 pmcid: 6821395 doi: 10.1016/j.cmet.2018.11.014
Carpenter, A. E. et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 7, R100 (2006).
pubmed: 17076895 pmcid: 1794559 doi: 10.1186/gb-2006-7-10-r100
Haubold, C. et al. Segmenting and tracking multiple dividing targets using ilastik. Adv. Anat. Embryol. Cell Biol. 219, 199–229 (2016).
pubmed: 27207368 doi: 10.1007/978-3-319-28549-8_8
Rueda, O. M. et al. Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature 567, 399–404 (2019).
pubmed: 30867590 pmcid: 6647838 doi: 10.1038/s41586-019-1007-8
Gottfried, E. et al. Expression of CD68 in non-myeloid cell types. Scand. J. Immunol. 67, 453–463 (2008).
pubmed: 18405323 doi: 10.1111/j.1365-3083.2008.02091.x
Costa, A. et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell 33, 463–479 (2018).
pubmed: 29455927 doi: 10.1016/j.ccell.2018.01.011
Mitra, A. K. et al. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov. 2, 1100–1108 (2012).
pubmed: 23171795 pmcid: 3685866 doi: 10.1158/2159-8290.CD-12-0206
Stingl, J. & Caldas, C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat. Rev. Cancer 7, 791 (2007).
pubmed: 17851544 doi: 10.1038/nrc2212
Schapiro, D. et al. histoCAT: analysis of cell phenotypes and interactions in multiplex image cytometry data. Nat. Methods 14, 873–876 (2017).
Akavia, U. D. et al. An integrated approach to uncover drivers of cancer. Cell 143, 1005–1017 (2010).
pubmed: 21129771 pmcid: 3013278 doi: 10.1016/j.cell.2010.11.013
Slamon, D. J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712 (1989).
pubmed: 2470152 doi: 10.1126/science.2470152
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61 (2015).
pubmed: 25594174 pmcid: 4856474 doi: 10.1016/j.cell.2014.12.033
Facciabene, A. et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T
pubmed: 21753853 doi: 10.1038/nature10169
Dawson, S. J., Rueda, O. M., Aparicio, S. & Caldas, C. A new genome-driven integrated classification of breast cancer and its implications. EMBO J. 32, 617–628 (2013).
pubmed: 23395906 pmcid: 3590990 doi: 10.1038/emboj.2013.19
Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018).
Bodenmiller, B. Multiplexed epitope-based tissue imaging for discovery and healthcare applications. Cell Syst. 2, 225–238 (2016).
pubmed: 27135535 doi: 10.1016/j.cels.2016.03.008
Ali, H. R. et al. Association between CD8
pubmed: 24915873 doi: 10.1093/annonc/mdu191
Ali, H. R., Chlon, L., Pharoah, P. D., Markowetz, F. & Caldas, C. Patterns of immune infiltration in breast cancer and their clinical implications: a gene-expression-based retrospective study. PLoS Med. 13, e1002194 (2016).
pubmed: 27959923 pmcid: 5154505 doi: 10.1371/journal.pmed.1002194
Reis-Filho, J. S. & Pusztai, L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 378, 1812–1823 (2011).
pubmed: 22098854 doi: 10.1016/S0140-6736(11)61539-0
Ross-Innes, C. S. et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481, 389–393 (2012).
pubmed: 22217937 pmcid: 3272464 doi: 10.1038/nature10730
Patten, D. K. et al. Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer. Nat. Med. 24, 1469–1480 (2018).
pubmed: 30038216 pmcid: 6130800 doi: 10.1038/s41591-018-0091-x
Barsoum, I. B., Koti, M., Siemens, D. R. & Graham, C. H. Mechanisms of hypoxia-mediated immune escape in cancer. Cancer Res. 74, 7185–7190 (2014).
pubmed: 25344227 doi: 10.1158/0008-5472.CAN-14-2598
Bristow, R. G. & Hill, R. P. Hypoxia, DNA repair and genetic instability. Nat. Rev. Cancer 8, 180–192 (2008).
pubmed: 18273037 doi: 10.1038/nrc2344
Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8, 1136 (2017).
pubmed: 29070816 pmcid: 5656607 doi: 10.1038/s41467-017-01062-w
Kalluri, R. & Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer 6, 392–401 (2006).
pubmed: 16572188 doi: 10.1038/nrc1877
Ozdemir, B. C. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719–734 (2014).
pubmed: 24856586 pmcid: 4180632 doi: 10.1016/j.ccr.2014.04.005
Rhim, A. D. et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25, 735–747 (2014).
pubmed: 24856585 pmcid: 4096698 doi: 10.1016/j.ccr.2014.04.021
Rakha, E. A. et al. Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J. Clin. Oncol. 28, 99–104 (2010).
pubmed: 19917872 doi: 10.1200/JCO.2009.23.5051
Mukherjee, A. et al. Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort. NPJ Breast Cancer 4, 5 (2018).
pubmed: 29532008 pmcid: 5841292 doi: 10.1038/s41523-018-0056-8
Dunning, M. J., Smith, M. L., Ritchie, M. E. & Tavare, S. beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 23, 2183–2184 (2007).
pubmed: 17586828 doi: 10.1093/bioinformatics/btm311
Kononen, J. et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 4, 844–847 (1998).
pubmed: 9662379 doi: 10.1038/nm0798-844
Catena, R., Ozcan, A., Jacobs, A., Chevrier, S. & Bodenmiller, B. AirLab: a cloud-based platform to manage and share antibody-based single-cell research. Genome Biol. 17, 142 (2016).
pubmed: 27356760 pmcid: 4928244 doi: 10.1186/s13059-016-1006-0
Keren, L. et al. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell 174, 1373–1387 (2018).
pubmed: 30193111 pmcid: 6132072 doi: 10.1016/j.cell.2018.08.039
Van Gassen, S. et al. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A 87, 636–645 (2015).
pubmed: 25573116 doi: 10.1002/cyto.a.22625
Levine, J. H. et al. Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis. Cell 162, 184–197 (2015).
pubmed: 26095251 pmcid: 4508757 doi: 10.1016/j.cell.2015.05.047
Phipson, B. & Smyth, G. K. Permutation P-values should never be zero: calculating exact P-values when permutations are randomly drawn. Stat. Appl. Genet. Mol. Biol. 9, Article39 (2010).
pubmed: 21044043 doi: 10.2202/1544-6115.1585
Newson, R. B. Frequentist q-values for multiple-test procedures. Stata J. 10, 568–584 (2010).
doi: 10.1177/1536867X1101000403
Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289–300 (1995).
Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160–1167 (2009).
pubmed: 19204204 pmcid: 2667820 doi: 10.1200/JCO.2008.18.1370
Yu, G. & He, Q. Y. ReactomePA: an R/Bioconductor package for Reactome pathway analysis and visualization. Mol. Biosyst.12, 477–479 (2016).
pubmed: 26661513 doi: 10.1039/C5MB00663E
Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics 16, 284–287 (2012).
pubmed: 22455463 pmcid: 3339379 doi: 10.1089/omi.2011.0118
Van Loo, P. et al. Allele-specific copy number analysis of tumors. Proc. Natl Acad. Sci. USA 107, 16910–16915 (2010).
pubmed: 20837533 pmcid: 2947907 doi: 10.1073/pnas.1009843107
Sondka, Z. et al. The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat. Rev. Cancer 18, 696–705 (2018).
Gloor, G. B., Macklaim, J. M., Pawlowsky-Glahn, V. & Egozcue, J. J. Microbiome datasets are compositional: and this is not optional. Front. Microbiol. 8, 2224 (2017).
pubmed: 29187837 pmcid: 5695134 doi: 10.3389/fmicb.2017.02224
Blows, F. et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 7, e1000279 (2010).
pubmed: 20520800 pmcid: 2876119 doi: 10.1371/journal.pmed.1000279
Friedman, J. H., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33 (1), 1–22 (2010).
R Core Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2016).

Auteurs

H Raza Ali (HR)

Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
CRUK Cambridge Institute, University of Cambridge, Cambridge, UK.

Hartland W Jackson (HW)

Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.

Vito R T Zanotelli (VRT)

Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.

Esther Danenberg (E)

Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.

Jana R Fischer (JR)

Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.

Helen Bardwell (H)

CRUK Cambridge Institute, University of Cambridge, Cambridge, UK.

Elena Provenzano (E)

Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust and NIHR Cambridge Biomedical Research Centre, Cambridge, UK.

Oscar M Rueda (OM)

CRUK Cambridge Institute, University of Cambridge, Cambridge, UK.

Suet-Feung Chin (SF)

CRUK Cambridge Institute, University of Cambridge, Cambridge, UK.

Samuel Aparicio (S)

Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.

Carlos Caldas (C)

CRUK Cambridge Institute, University of Cambridge, Cambridge, UK. carlos.caldas@cruk.cam.ac.uk.
Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust and NIHR Cambridge Biomedical Research Centre, Cambridge, UK. carlos.caldas@cruk.cam.ac.uk.

Bernd Bodenmiller (B)

Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland. bernd.bodenmiller@imls.uzh.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH